ObvioHealth Introduces ObvioGo 2.2: Transforming Study Management with AI-Driven Innovation

AI-Driven Enhancements in ObvioGo 2.2 Redefine Efficiency, Compliance, and Innovation in Clinical Trial Management  NEW YORK, Jan. 14, 2025 /PRNewswire/ — ObvioHealth, a global leader in digital clinical trial solutions, today announced the release of ObvioGo 2.2, the latest version of its innovative … Read More 

RheumaGen, Inc. Launches with $15 Million Series A Financing to Advance a New Class of HLA Gene-Editing Therapies for Major Autoimmune Diseases

Company focused on editing the human leukocyte antigen (HLA) to transform autoimmunity Lead program, RG0401, in development for treatment-resistant or refractory rheumatoid arthritis (RA), as a one-time, curative treatment AURORA, CO, January 9, 2025 – RheumaGen, Inc., a cell and … Read More 

Jaguar Health Family Company Napo Therapeutics Named “Best Pharmaceuticals Innovator of the Year – Europe”

Established in Milan, Italy in 2021, Napo Therapeutics is focused on expanding access to crofelemer, Jaguar’s novel oral plant-based prescription drug, in Europe for orphan and/or rare diseases SAN FRANCISCO, CA / ACCESSWIRE / November 19, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that Jaguar family company Napo Therapeutics … Read More 

PulseSight Therapeutics to Present Data on PST-611 at EVER Congress 2024

PARIS, Oct. 07, 2024 (GLOBE NEWSWIRE) — PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, is pleased to confirm that it will be presenting data on its lead program PST-611, expressing human … Read More 

Fibronostics Announces Partnership with Stone Diagnostics

SANTA ROSA BEACH, Fla. and SINGAPORE, Oct. 10, 2023 – Fibronostics, a global leader in non-invasive, AI-driven diagnostic testing for *MAFLD/MASH patients, announced today a strategic partnership with Stone Diagnostics, a leading provider of laboratory services in the United States.  Stone Diagnostics will provide Physicians … Read More 

Spexis provides business update and announces financial results for the first half of 2023

Ad hoc announcement pursuant to Art. 53 LR Balixafortide, a potent CXCR4 inhibitor, to be evaluated for the treatment of pancreatic ductal adenocarcinoma (PDAC) Spexis closed capital commitments totaling USD $7.5 million supporting Phase 3 ColiFin® program in cystic fibrosis … Read More 

Spexis announces closing of capital commitment of USD 4.5 million from SPRIM Global Investments (SGI) to enable initiation of ColiFin® Phase 3 study

Ad hoc announcement pursuant to Art. 53 LR Funding to enable immediate initiation of the COPILOT study, the first of two Phase 3 ColiFin® studies; first-patient-in expected in June 2023 Commitment structured as a mix of secured debt and subordinated debt … Read More 

AUM Biosciences, SCG Cell Therapy, Blood And Hello Health Disclose Updates

AUM Biosciences, a Singapore-headquartered biotech company focused on precision oncology therapeutics, allotted shares worth $11.8 million earlier this week. Everlife Holdings, a market access and distribution company in India and Southeast Asia, received the bulk of the new shares. AUM Biosciences … Read More 

1nHealth Launches Site Advisory Board to Prioritize Site Voice

The digital patient recruitment company tapped industry experts to monitor and provide feedback to best optimize its ability to serve study sites. ORLANDO, Fla., March 28, 2023 (Newswire.com) – Today, 1nHealth launched its Site Advisory Board, a consortium of research … Read More 

STALICLA and Firefly Neuroscience enter Partnership Agreement for the Development of Electroencephalogram (EEG) as a Biomarker for Subgroups of Patients with ASD

PRESS RELEASE STALICLA signs exclusive in-licensing agreement for late-stage clinical neuropsychiatric and neurodevelopmental disorder treatment The transaction with Novartis reinforces STALICLA’s position as the leading developer of precision medicines for neurodevelopmental disorders and heralds the expansion of its portfolio into wider neuropsychiatric indications Geneva, SWITZERLAND – 9 January 2023, STALICLA SA, a clinical-stage biotech company advancing the first precision neurobiology … Read More 

STALICLA signs exclusive in-licensing agreement for late-stage clinical neuropsychiatric and neurodevelopmental disorder treatment

PRESS RELEASE STALICLA signs exclusive in-licensing agreement for late-stage clinical neuropsychiatric and neurodevelopmental disorder treatment The transaction with Novartis reinforces STALICLA’s position as the leading developer of precision medicines for neurodevelopmental disorders and heralds the expansion of its portfolio into wider neuropsychiatric indications Geneva, SWITZERLAND – 9 January 2023, STALICLA SA, a clinical-stage biotech company advancing the first precision neurobiology … Read More 

ObvioHealth Introduces ObvioGo™, a Next-Generation DCT Platform and Mobile Application Delivering Stronger Evidence

NEW YORK – September 14, 2022 –  ObvioHealth,  a pioneering virtual research organization (VRO), announces the launch of ObvioGo, a next-generation decentralized clinical trial platform and mobile application powered to deliver stronger evidence of therapeutic efficacy and safety. ‍ While the pandemic … Read More 

Coronavirus Outbreak: Medical Staff Vulnerable, Telemedicine the Solution?

Medical personnel working on the frontline to prevent the spread of the COVID-19 (coronavirus) are susceptible to infection, we believe telemedicine can help to mitigate this risk. … Read More 

Ventures Day Singapore 2020: Post-event highlights

Investors Looking at Presentations about Biotech and Digital Health

Following our three successful past events – June 2017 & January 2019 in Singapore and April 2019 in New York – SPRIM held another exciting Ventures Day at our brand new auditorium in Singapore. Our CEOs, science/tech experts, and strategic innovators presented … Read More 

Real World Data and Evidence Revolutionize Clinical Research

The U.S. FDA is aware the drug approval process can often be strenuous, consuming large amounts of time and money. That’s why they’ve made a commitment to consider real-world data and evidence in the approval of new drug indications resulting in a more efficient approach for manufacturers. … Read More 

Disruptive Healthcare Trends: 5 Innovations to Look for in 2020

From blockchain to 3D printing – we’ve pinpointed the biggest tech trends in health innovation and what they mean for healthcare in 2020.  You’re likely familiar with many of these trends, however, advances in the industry have allowed for new applications … Read More 

U.S. Recycling Stream in Shambles: How CPG Companies can Change the Game

Forty percent of the world’s plastic usage comes from packaging – packaging of food, beverage, personal care, cosmetic, toys and almost every other product on store shelves. With the U.S. inefficiencies and China’s crackdown, reducing the amount of plastic that enters circulation is becoming increasingly important. … Read More 

How SPRIM’s Practice Areas & Sister Companies Work Together to Build the Future of Health

A breakdown of the four practices areas SPRIM utilizes to help its clients meet their commercial endpoints: strategy and innovation, regulatory and scientific affairs, research and clinical services and medical marketing and engagement. … Read More 

Path-to-Market: How Regulatory Technology Can Help Companies Expand to Asia

The booming middle-class in Asia and the accompanying influx of consumer spending is an enticing area for companies looking to capitalize on. RegTech can reduce the regulatory obstacles that FMCG and medical device companies face when expanding, enabling them to bring their products to market in more efficient and cost-effective ways. … Read More 

RegTech: Easing the Burden of Compliance for FMCG

This article explains the emergence of RegTech as an opportunity in the consumer product goods industry, as food and beverage, personal care, pharmaceutical, and cosmetic companies often struggle to stay updated on the regulations in a region or country. … Read More 

Combating a Tainted Market: 3 Ways to Substantiate a Dietary Supplement Product

As media attention increases around the risk of “bad” products on the market, consumers are becoming increasingly wary of the presence of potentially harmful, misbranded dietary supplements. If this trend continues, we predict that customers will not only become more selective when buying products, but that overall trust in the industry will begin to weaken.  So, how can dietary supplement companies selling legitimate products ensure they aren’t looped in with the bad apples? … Read More 

AC Health Announces Investment in Fibronostics

Ayala Healthcare Holdings announced an investment in SPRIM’s portfolio company, Fibronostics. As part of the partnership, AC Health will launch two Fibronostics products, LiverFAST and HealthFACTR, in its FamilyDOC clinics in the Philippines. … Read More 

Bring Your Own Device in Clinical Research: The Four C’s

“BYOD” or “bring your own device” is the future of clinical studies, and sponsors are embracing what will become the new standard. Subjects using their own devices to fill out diaries and input data is not only less expensive for … Read More 

Video: Celebrating 15 Years with Unilever

SPRIM has worked with dozens of Unilever brands on projects ranging from market rollouts and HCP engagement to business innovation. … Read More 

The Forgotten Piece to the Adherence Puzzle

Medicines don’t work if patients don’t take them. It’s one of the biggest culprits in healthcare’s nearly $300 billion problem. Estimates show poor adherence causes approximately 125,000 deaths and at least 10 percent of hospitalizations annually. Patient Engagement Programs Pharma companies are actively … Read More 

5 Big Product Development Mistakes

The most common missteps SPRIM sees when working with clients to developing and bringing new products to the market. … Read More 

SPRIM’s Quarterly Ventures Day Meeting in New York

SPRIM Ventures in partnership with Tikehau Capital is hosting a Ventures Day event in New York on April 24. … Read More 

Fibronostics Corporate Update

Fibronostics presented its corporate strategy at the second annual TKS 1 Investor Day in Singapore. The event was attended by current and potential investors in the TKS 1 fund, including venture capitalists, strategic investors, family offices and leaders from the healthcare industry. … Read More 

Evid Science: AI Can Read & Share the Latest Medical Research with Doctors

Evid Science’s founder and CEO, Matt Michelson, spoke to Thrive Global about the future of healthcare and how AI is transforming the industry. Evid Science is helping to “free” all of the scientific data locked away in publications and journals.   … Read More 

TKS 1 Investor Day 2019 in Singapore: Post Event Highlights

Going strong in its second time, together with Tikehau Capital, SPRIM held TKS 1 Investor Day on Friday, January 25, 2019, at the Four Seasons Hotel in Singapore. We invited all teams, shareholders, and partners of the ventures for this event … … Read More 

RegAsk, a Healthcare RegTech Startup, Secures Venture Capital Funding in a Seed Round to Pursue Growth

RegAsk uses artificial intelligence to answer regulatory questions, including inquiries about path-to-market, path-to-claim, product registration and regulatory strategy. … Read More 

Evid Science Receives Seed Capital to Advance Clinical AI Platform

LOS ANGELES, CA (February 15, 2018) – Evid Science, an artificial intelligence (AI) company for the pharmaceutical industry, has successfully secured seed funding from TKS I, a new private equity fund dedicated to early-stage life science companies. “Our technology is … Read More 

Duke-NUS Commercializes Discovery to Deliver Therapeutics Across Blood Brain Barrier

Intellectual property (IP) derived from discoveries made at Duke-NUS Medical School (Duke-NUS) have been licensed to a newly formed biotech start-up, Travecta Therapeutics Pte Ltd, a Singapore-based drug discovery company. Travecta plans to use the Duke-NUS technology to develop new … Read More 

Tackling the blood-brain barrier: Duke-NUS discovery leads to startup Travecta

HONG KONG – Travecta Therapeutics Pte Ltd. is the latest startup to join Singapore’s biotech block. The newly formed drug discovery company is based on intellectual property derived from discoveries made at Duke-NUS Medical School (Duke-NUS). Travecta is based on … Read More 

Travecta Therapeutics Appoints Douglas C. Hicks as Chief Business Officer

PHILADELPHIA — Sept. 13 2018 – Travecta Therapeutics, an emerging biotech company developing a platform that leverages its proprietary knowledge of the MFSD2a Transport for the targeted delivery of therapeutic agents across the blood-brain barrier, announces it has appointed Douglas … Read More 

The Role of E-commerce in Product Innovation

A R&D Guide Outlining Ways To Use E-commerce For A More Effective Analysis On A Future Product’s Success. … Read More 

This is why your patient engagement dollars are wasted.

A Patient (and consultant’s) Point-of-View on Patient Services Imagine, as a patient, you leave the doctor’s office having been diagnosed with a chronic disease. The treatment calls for heavy doses of medication and changed lifestyle habits. You pestered the doctor … Read More 

Forbes: ObvioHealth To Transform Clinical Studies

ObvioHealth, supported by SPRIM, releases a Mobile App that is positioned to transform clinical studies globally. … Read More 

ObvioHealth Announces Mobile Application

ORLANDO, Fla.–(BUSINESS WIRE)–ObvioHealth, a global medical technology company, announces the launch of its mobile application for site-less clinical studies— the ObvioHealth app. The app removes barriers currently troubling the clinical research industry by improving convenience for study subjects, enhancing compliance, … Read More 

ObvioHealth Raises $3 Million in Series A Funding

ObvioHealth, a Singapore and Orlando-based company offering mobile and “site-less” clinical trials, said on Friday it has raised US$3 million in Series A funding. The company is focused on making clinical trials faster and more cost-effective by digitizing the entire process … Read More